Effective screen for amyloid β aggregation inhibitor using amyloid β-conjugated gold nanoparticles

International Journal of Nanomedicine

Volumn 6, Issue 1, 2011, Pages 1-12

  Han, Sun Ho ^a   Chang, Yu Jin ^a   Jung, Eun Sun ^a   Kim, Jong Won ^b   Na, Duk Lyul ^b   Mook Jung, Inhee ^a  

^a Seoul National University   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Aggregation; Alzheimer's disease; Amyloid ; Diagnosis; Gold nanoparticle; Transthyretin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; GOLD NANOPARTICLE; PREALBUMIN; THIOFLAVINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING ASSAY; CASE REPORT; CONTROLLED STUDY; HUMAN; NERVE DEGENERATION; OPTICAL DENSITY; PARTICLE SIZE; PATHOGENESIS; PRECIPITATION; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SUPERNATANT; SURFACE PLASMON RESONANCE; TRANSMISSION ELECTRON MICROSCOPY;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; CHEMICAL PRECIPITATION; DRUG DISCOVERY; GOLD; HUMANS; METAL NANOPARTICLES; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDE FRAGMENTS; PREALBUMIN; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY;

EID: 79251506643     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S15278     Document Type: Article

References (24)

1. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352-357.
2. Mucke L. Neuroscience: Alzheimer's disease. Nature. 2009;461: 895-897.
3. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296:1991-1995.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297: 353-356.
5. Holtzman DM. Alzheimer's disease: moving towards a vaccine. Nature. 2008;454:418-420.
6. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535-539.
7. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720-724.
8. Bohrmann B, Tjernberg L, Kuner P, et al. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem. 1999;274:15990-15995.
9. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I. Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor. PLoS One. 2008;3:e2899.
10. Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994;91:8368-8372.
11. Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22:7380-7388.
12. Hansson SF, Andreasson U, Wall M, et al. Reduced levels of amyloid- beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis. 2009;16:389-397.
13. Hu M, Chen J, Li ZY, et al. Gold nanostructures: engineering their plasmonic properties for biomedical applications. Chem Soc Rev. 2006; 35:1084-1094.
14. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature. 1996;382:607-609.
15. Linse S, Cabaleiro-Lago C, Xue WF, et al. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A. 2007;104: 8691-8696.
16. Eghtedari M, Liopo AV, Copland JA, Oraevsky AA, Motamedi M. Engineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells. Nano Lett. 2009;9: 287-291.
17. Kogan MJ, Bastus NG, Amigo R, et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 2006;6: 110-115.
18. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009; 38:1759-1782.
19. Groenning M, Olsen L, van de Weert M, Flink JM, Frokjaer S, Jorgensen FS. Study on the binding of Thioflavin T to betasheet- rich and non-beta-sheet cavities. J Struct Biol. 2007;158: 358-369.
20. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol. 2001;159:1993-2000.
21. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998;158:47-52.
22. Curtain CC, Ali F, Volitakis I, et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membranepenetrating structure containing superoxide dismutase-like subunits. J Biol Chem. 2001;276:20466-20473.
23. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998;273:12817-12826.
24. Martins IC, Kuperstein I, Wilkinson H, et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 2008;27:224-233.